Jacobi Capital Management LLC Has $1.04 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

Jacobi Capital Management LLC trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,196 shares of the medical instruments supplier’s stock after selling 200 shares during the period. Jacobi Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $1,038,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Ridgewood Investments LLC boosted its position in Becton, Dickinson and Company by 1.5% in the 1st quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock valued at $731,000 after buying an additional 43 shares during the last quarter. Key Client Fiduciary Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 2.6% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock worth $424,000 after purchasing an additional 43 shares during the last quarter. CWM LLC boosted its position in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after purchasing an additional 46 shares during the last quarter. S.A. Mason LLC boosted its position in shares of Becton, Dickinson and Company by 3.5% in the 4th quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 48 shares during the last quarter. Finally, Edge Capital Group LLC boosted its position in shares of Becton, Dickinson and Company by 3.1% in the 4th quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after purchasing an additional 48 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. The Goldman Sachs Group started coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target on the stock. Citigroup reduced their price target on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Finally, Evercore ISI dropped their price target on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $280.14.

Insider Buying and Selling

In other news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, EVP Roland Goette sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the sale, the executive vice president now owns 11,308 shares in the company, valued at $2,676,942.84. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 8,615 shares of company stock worth $2,033,381. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.2 %

Shares of NYSE:BDX traded up $0.35 during midday trading on Monday, reaching $231.09. The company had a trading volume of 866,733 shares, compared to its average volume of 1,427,038. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average price is $232.42 and its 200 day moving average price is $236.40. The stock has a market cap of $66.79 billion, a PE ratio of 50.86, a P/E/G ratio of 2.02 and a beta of 0.42. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. Becton, Dickinson and Company’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.86 earnings per share. Research analysts forecast that Becton, Dickinson and Company will post 13.04 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Monday, June 10th were issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date was Monday, June 10th. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.